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Poly(amino acid)-Polyester Graft Copolymer Nanoparticles for the 
Acid-Mediated Release of Doxorubicin 
Daniel J. Price ? ?1 Mthulisi Khuphe ? ?1 Robert P. W. Davies,2 James R. McLaughlan,3 Nicola Ingram1,4 
and Paul D. Thornton1* 
Biodegradable polymers have emerged as highly effective 
drug delivery vehicles. We combime N-carboxyanhydride and 
O-carboxyanhydride ring opening polymerisations to 
synthesise a poly(amino acid)-polyester graft copolymer 
capable of encapsulating, and subsequently releasing 
doxorubicin via acid-mediated hydrolysis. Consequently, the 
nanoparticles detailed are extremely promising vehicles for 
the controlled delivery of chemotherapeutic agents. 
The pharmaceutical industry is in a constant state of flux, with 
the past 30 years seeing the rise of multiple, paradigm-shifting 
scientific advances such as high-throughput screening, 
combinatorial chemistry, genomics, proteomics and 
computational chemistry.1 This has resulted in an exponential 
increase in the number of viable targets and chemical 
substrates available, often in the form of vast compound 
libraries and databases.2 In the past decade alone, the number 
of therapeutic compounds in development has increased by 
62%.3 However, somewhat counter-intuitively, the number of 
new drugs approved by the USA Food Drug Administration 
(FDA) has been in decline since the 1990s, with only 25% 
approved in 2000-2010 compared with 1990-2000.4 Poor 
compound pharmacokinetics are frequently discussed as the 
most significant contributor to preventing effective therapeutic 
treatment. 
Utilising polymeric carriers for targeted drug delivery enables 
the distribution of hydrophobic drug molecules in vivo, prior to 
drug release and deployment at a target site.5 In addition, the 
polymer restricts undesired and non-selective drug-receptor 
interactions, an imperative requirement for the delivery of toxic 
anti-cancer drugs to minimise the extremely unpleasant side 
effects that are associated with prolonged chemotherapy.6 In 
particular, polyanhydrides,8 poly(amino acid)s,9 poly(alkyl 
cyanoacrylate)s10 and polyorthoesters11 have been highlighted 
as promising drug delivery vehicles. Such polymers are designed 
undergo programmed hydrolysis at a target side to liberate the 
therapeutic agent following polymer degradation.   
Poly(amino acid)s synthesised by N-carboxyanhydride (NCA) 
ring-opening polymerisation (ROP) are attractive candidates for 
utilisation as drug delivery vehicles as they can readily self-
assemble in aqueous solution to form discrete 
nanostructures.12 Additionally, poly(amino acid)s possess a 
diverse chemical identity with 20 canonical amino acid varieties 
available, not to mention the multitude of non-classical amino 
acids. However, poly(amino acid)s are not readily susceptible to 
hydrolysis at physiologically relevant pH levels, and as such are 
of limited use for acid-mediated controlled drug delivery. To 
overcome this obstacle, a pH-responsive element may be 
incorporated into the polymer that is susceptible to acid-
mediated hydrolysis, which prompts polymer degradation, and 
payload release. 
Polyesters are susceptible to hydrolysis at pH levels comparable 
to that of the cancerous tumour microenvironment.13 
Measured tumour extracellular pH values of many solid 
tumours range from pH 6.5 to pH 7.2, and the pH within 
cancerous cells may be between pH 5.0 and pH 6.0 in 
endosomes, and between pH 4.0 and pH 5.0 in lysosomes.14 The 
synthesis of pendant-functionalised polyesters may be achieved 
by utilising O-carboxyanhydride (OCA) ROP. Such functionality 
may be used to promote polymeric self-assembly and/or be 
exploited for further (bio)chemical modification. Combining 
NCA ROP and OCA ROP enables the production of polymers 
capable of self-assembly to form nanoparticles in aqueous 
solution, but crucially also yields polymers that can readily 
partake in acid-mediated hydrolysis to enable payload release. 
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Scheme 1: (1) ROP of Serine (Ser) NCA may be conducted from a 
primary amine-presenting molecue to produce OBz-protected 
poly(Ser). In this instance benzylamine was utilised as the initiator. 
(2) Deprotection of OBz-protected poly(Ser), using trifluoroacetic 
acid and HBr in ethanoic acid solvent, to yield poly(Ser). (3) Poly(Ser) 
(-OH) initiated ROP of Phenylalanine (Phe) OCA, to yield poly(Ser)-
graft-poly(Phe ɲ-hydroxyacid). 4-Dimethylaminopyridine (DMAP) 
was utilised as the catalyst in this instance. 
We report the synthesis of a novel poly(amino acid)-graft- 
polyester coploymer by sequential NCA and OCA ROP. Poly(Ser)   
was created by NCA ROP as the polymer backbone onto which 
the OCA of phenylalanine was subsequently grafted. Combining 
NCA ROP and OCA ROP in this manner permits the production 
of a polymer that possesses the capability to self-assemble to 
form nanoparticles in aqueous solution, entrap doxorubicin, and 
undergo degradation to release the therapeutic payload in 
response to acidic media. It is envisaged that the copolymers 
produced may be exploited to create materials that are of 
significance as  novel, highly-effective, controlled release systems 
for the delivery of chemotherapeutic agents to acidic cancerous 
tissue. 
The proposed macromolecular system is detailed in Scheme 1. 
Firstly, the monomers O-Benzyl-L-Ser NCA and Phe OCA were 
synthesised before poly(O-benzyl-L-Ser) was produced by 
benzylamine-initiated NCA ROP. Upon the cleavage of the 
benzyl protecting groups, poly(Ser) was yielded and used to 
initiate the ROP of phenylalanine OCA in the presence of DMAP, 
to afford the desired graft copolymer. The base activation of the 
monomer with multiple hydrogen bonds from DMAP is 
reported to be more energetically favourable than the standard 
nucleophilic activation achieved by the monomer alone.15 In 
ĂĚĚŝƚŝŽŶ ? ŝƚ ǁĂƐ ŚǇƉŽƚŚĞƐŝƐĞĚ ƚŚĂƚ DW ŵĂǇ ĂĐƚ ǀŝĂ Ă  ?ƚǁŽ-
ƉƌŽŶŐĞĚ ?ĂĐƚŝǀĂƚŝŽŶĂƉƉƌŽĂĐŚ ?ƚŚƌŽƵŐŚŝƚƐďĂƐŝĐŶŝƚƌŽŐĞŶĐĞŶƚƌĞ
and acidic O-hydrogens, making it a bifunctional catalyst.  A 
range of polymers were produced that possessed varying ratios 
of poly(amino acid) and polyester segments within their 
composition (ESI Tables S1 and Table S2). 
The capability of the polymers produced to self-assemble and 
form nanoparticles in aqueous medium was then assessed. 
Poly(Ser) consisting of 9.6, 18.7 and 19.6 amino acid monomer  
Table 1: Mean particle size and PDI values for a series of graft 
copolymers, as determined by DLS. Data is presented as mean ± 
SD (n = 3).  
repeat units, as determined by 1H NMR, was used to graft 
varying degrees of poly(Phe ɲ-hydroxyacid) from the pendant 
hydroxyl groups present (Table 1). In all cases, nanoparticles 
ǁĞƌĞ ƉƌŽĚƵĐĞĚ ĨŽůůŽǁŝŶŐ ƚŚĞ  ?ĚƌŽƉƉŝŶŐ-ŝŶ ? ŵĞƚŚŽĚ ŽĨ ƐĞůĨ-
assembly, in which the polymer is expelled from DMF into PBS 
solution (pH 7.4). The extent of Phe OCA grafting was relatively 
low to ensure that polymer precipitation did not occur from 
DMF, but sufficiently high to ensure nanoparticle formation. 
The polydispersity index values obtained for the nanoparticlees 
crĞĂƚĞĚƌĂŶŐĞĚĨƌŽŵŚĂǀŝŶŐĂŶĂƌƌŽǁĚŝƐƚƌŝďƵƚŝŽŶ ?W/A䜀  ? ?? ?ƚŽ
possessing a moderately polydisperse distribution (0.1 > PDI < 
0.4).  
From these results, poly(Ser)19.6-graft-poly(Phe ɲ-hydroxyacid)6 
(Table 1, Entry 1) was deemed to be the most attractive 
candidate for use as a drug delivery vehicle due to the average 
size and the narrow polydispersity of the nanoparticles 
produced. As a result, this polymer was progressed into proof-
of-concept studies, which aimed to demonstrate successful 
encapsulation and subsequent release of the chemotherapeutic 
doxorubicin from the formed nanoparticles. After successful 
conversion to the free-base, doxorubicin solution (chloroform) 
was added to the nanoprecipitation solution of the polymer in 
pH 7.4 PBS solution, and the mixture left overnight. It was 
observed that after 12 hours of stirring at room temperature, 
the chloroform layer had completely disappeared and the 
aqueous portion of the mixture had developed a purple-red 
hue, indicating that the nanoparticles had successfully 
encapsulated the doxorubicin (ESI Figure S11, inset). This 
solution was then dialysed to allow any un-encapsulated 
doxorubicin to be isolated from the nanoparticles, which were 
subsequently lyophilised. Post-dialysis, the colour remained 
and the dialysis supernatant was shown by Uv-vis spectroscopy 
to have no doxorubicin present, suggesting complete 
encapsulation within the polymer nanoparticles.  The drug-
encapsulation efficiency of poly(Ser)19.6-graft-poly(Phe ɲ-
hydroxyacid)6 nanoparticles was 52.3% ± 6.2% and the drug 
loading content of the nanoparticles was 2.90% ± 1.3% (w/w). 
The particle size and morphology of a sample of doxorubicin-
loaded polymer was then assessed by DLS and SEM. It was 
observed that after the encapsulation of doxorubicin, 
nanoparticles of 118 nm mean diameter formed (ESI Figure 
S11). This increased swelling from the initial 90 nm adds further 
confidence to confirm the successful encapsulation of 
doxorubicin within the nanoparticles. 
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Figure 1: Doxorubicin release from nanoparticles consisting of  that 
are maintained in solution of pH 5.0 (n) and pH 7.4 (s). Release % 
has been adjusted to account for the assumed equal 
concentration of doxorubicin that could not be analysed (n=3). 
The potential for acid-mediated release of doxorubicin from the 
nanoparticles was then assessed.  For this purpose, a dialysis- 
setup was employed, whereby the doxorubicin-loaded 
nanoparticles were suspended in aqueous medium within a 
dialysis bag; released doxorubicin passes through the dialysis 
bag and into the surrounding medium of equal volume to that 
within the dialysis tubing, whilst unhydrolysed polymer 
nanoparticles, which are doxorubicin loaded, are retained 
within the dialysis tubing. Doxorubicin release to the exterior 
solution only occurs upon acid-mediated polymer degradation, 
which can then be quantified. Significant and rapid payload 
release occurred when doxorubicin nanoparticles were 
suspended in an acidic environment, although only the 
doxorubicin that passed to the outside of the dialysis bag could 
be measured. 47.7% of the loaded doxorubicin had passed 
through the dialysis membrane to the exterior solution after six 
days of incubation. This value is presented as 95.4% release in 
Figure 1 as it is assumed that the released doxorubicin 
concentration outside the dialysis tubing (which could be 
analysed) is equal to the concentration of released doxorubicin 
within the dialysis tubing (which could not be analysed), owing 
to the equal volume of solution internal and external to the 
dialysis membrane. The release of doxorubicin to the external 
dialysis medium is theoretically limited via simple diffusion 
kinetics to 50%. Conversely, only 4.0% (presented as 8.0% in the 
adjusted Figure 1) of loaded doxorubicin passed through the 
dialysis membrane to the exterior solution from nanoparticles 
that were maintained within an aqueous solution (pH 7.4) after 
six days, highlighting the requirement of an acidic environment 
to instigate substantial payload release.  
In order to support the positive release profile of doxorubicin 
from the nanoparticles stored within an acidic medium, a 
degradation study was carried out to correlate payload release 
with nanoparticle degradation. Nanoparticle samples were 
independently stored in buffer solution maintained at pH 5.0 
and buffer solution maintained at pH 7.4, and after 48 hours the 
size distribution of both samples was determined by DLS, and 
representative images obtained by SEM (Figure 2). The 
nanoparticles held in buffer solution of pH 7.4 possessed a 
mean diameter of 100 nm after 48 hours, and were clearly 
visible during SEM analysis. This contrasts to the nanoparticles 
that were maintained within acidic medium; these  
Figure 2: Top, DLS and SEM analysis reveal the maintained presence 
of Poly(Ser)-graft-poly(Phe ɲ-hydroxyacid) nanoparticles when they 
are maintained in PBS solution (pH 7.4). Bottom, The presence of 
nanoparticles was not detected by SLS or DLS analysis when they 
were incubated in acidic solution (pH 5.0). Scale bars represent 1 
ʅŵ. 
nanoparticles were not evident in either DLS or SEM analyses, 
suggesting that acid-mediated polymer degradation is 
responsible for the release of doxorubicin. Additionally, 
poly(serine)19.6-graft-ƉŽůǇ ?ƉŚĞŶǇůĂůĂŶŝŶĞ ɲ-hydroxyacid)6 
nanoparticles were maintained within acetate buffer (pH 5.0) 
for 48 hours to fully confirm acid-mediated ester hydrolysis as 
the cause of payload release. Following incubation, the polymer 
was dialysed (regenerated cellulose, MWCO 1,000 kDa) against 
DI water and then chloroform to remove all non-polymeric 
groups from the solution. 1H NMR was utilised to analyse the 
recovered polymer and confirmed the removal of grafted 
polyester side chains, as evidenced by the lack of peak at ~3.5 
ppm, following graft copolymer incubation in acidic media 
(Figure S13).    
To determine the in vitro cytotoxicity of poly(Ser)19.6-graft-
poly(Phe ɲ-hydroxyacid)6  nanoparticles and doxorubicin-
loaded poly(Ser)19.6-graft-poly(Phe ɲ- hydroxyacid)6 
nanoparticles against a non-cancerous and cancerous cell line, 
Alamar Blue and MTT assays were carried out, respectively.  
Against the non- cancerous cell line (L929 fibroblasts), all 
polymer concentrations of both loaded and unloaded 
nanoparticles indicated a cell viability of 80% and above at 12, 
24, 48 and 72 hours (Figure S14). MTT assays were then carried 
out to determine the in vitro cytotoxicity of poly(Ser)19.6-graft-
poly(Phe ɲ-hydroxyacid)6 nanoparticles and doxorubicin-loaded 
poly(Ser)19.6-graft-poly(Phe ɲ-hydroxyacid)6 nanoparticles 
against T47D cells. The blank polymer nanoparticles exhibited 
nominal cytotoxicity against the cells during a prolonged period 
of 72 hours, ƉĂƌƚŝĐƵůĂƌůǇ Ăƚ ƉŽůǇŵĞƌ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ A?  ? ? ? ?
ʅŐ ?ŵ>  ?&ŝŐƵƌĞ  ? ? ? At polymer ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ A?  ? ? ? ʅŐ ?ŵ> ? Ă
significant difference in the cytotoxicity of doxorubicin-loaded 
nanoparticles and nanoparticles that lack doxorubicin 
encapsulation was found. Differences between the cell viability 
of free doxorubicin and doxorubicin-loaded nanoparticles 
suggest that the polymeric  
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Figure 3: (a) The effect of blank polymer ŶĂŶŽƉĂƌƚŝĐůĞƐ  ?භ ? ?
doxorubicin-loaded polymer nanoparticles (Ŷ) and free dox (s) 
on the viability of T47D cells. Data is presented as mean ± SD 
(n=4). 
carrier inhibits doxorubicin-cell interaction prior to doxorubicin 
release, or that the process of endosome uptake of 
nanoparticles, followed by polymer hydrolysis and the 
endosomal escape of doxorubicin limits the activity of 
doxorubicin compared to free doxorubicin. Examination of the 
assay plates show the presence of solubilised formazan crystals, 
confirming the presence of viable cells whose viability was 
affected marginally by culturing them in the presence of blank 
nanoparticles for 72 hours (Figure S15). In contrast, the 
doxorubicin-loaded nanoparticles exhibited significant 
cytotoxicity against the cancerous cells (the IC50 value of dox-
loaded nanoparticles on T47D cells was 0.065 µg/mL). The 
viability of the cancerous cells reduced to zero after 72 hours of 
incubation with doxorubicin-loaded nanoparticles (doxorubicin 
ůŽĂĚŝŶŐƐA䠃?A?Ő ?ŵ>).  
In summary, NCA ROP and OCA ROP were combined to create 
poly(amino acid)-polyester graft copolymers that were capable 
of self-assembly in aqueous media to form discrete 
nanoparticles. The chemotherapeutic doxorubicin was 
encapsulated within the nanoparticles formed from 
poly(Ser)19.6-graft-poly(Phe ɲ-hydroxyacid)6, and remained 
encapsulated in response to a physiologically neutral 
environment. However, the polyester functionality of the 
nanoparticles granted an innate susceptibility to acid-mediated 
polymer hydrolysis. Consequently, nanoparticle degradation 
and doxorubicin release occurred when the nanoparticles were 
maintained within solution of pH 5.0. Both doxorubicin 
containing and blank nanoparticles were non-cytotoxic against 
non-cancerous L929 fibroblasts cells, as determined by Alamar 
Blue assays. Promisingly, MTT assays revealed that poly(Ser)19.6-
graft-poly(Phe ɲ-hydroxyacid)6 nanoparticles have limited 
cytotoxicity against T47D cancer cells, whilst doxorubicin-
loaded nanoparticles exhibited significant anticancer activity 
against the same cell line. The polymers reported are capable of 
releasing a chemotherapeutic agent in response to acidic 
environments, and are thus highly promising candidates to be 
utilised for controlled therapeutic release at acidic, cancerous, 
sites.  
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